MeSH term
Frequency | Condition_Probility | Humans | 500 | 0.0 |
Adult | 94 | 0.0 |
Aged | 13 | 0.0 |
Antibodies, Anti-Idiotypic/immunology | 2 | 5.0 |
B-Lymphocytes/*immunology | 41 | 5.0 |
Calcium/metabolism | 4 | 0.0 |
Female | 110 | 0.0 |
Male | 119 | 0.0 |
Middle Aged | 62 | 0.0 |
Receptors, Complement 3d/*physiology | 12 | 70.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 22 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 200 | 0.0 |
Acute Disease | 21 | 0.0 |
Adolescent | 71 | 0.0 |
*Bone Marrow Purging | 6 | 24.0 |
Bone Marrow Transplantation/*methods | 6 | 13.0 |
Child | 69 | 0.0 |
Child, Preschool | 50 | 0.0 |
Disease-Free Survival | 27 | 2.0 |
Follow-Up Studies | 15 | 0.0 |
Infant | 34 | 0.0 |
Leukocyte Count | 5 | 0.0 |
Multivariate Analysis | 7 | 0.0 |
Prognosis | 22 | 0.0 |
Recurrence | 35 | 2.0 |
Remission Induction | 30 | 5.0 |
Transplantation, Autologous | 29 | 7.0 |
Base Sequence | 52 | 0.0 |
DNA Mutational Analysis | 5 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 16 | 0.0 |
Molecular Sequence Data | 86 | 0.0 |
Research Support, Non-U.S. Gov't | 323 | 0.0 |
Tumor Cells, Cultured | 40 | 0.0 |
Bone Marrow Purging | 3 | 13.0 |
*Bone Marrow Transplantation/adverse effects/mortality | 2 | 50.0 |
Comparative Study | 62 | 0.0 |
Graft Survival | 9 | 2.0 |
Incidence | 2 | 0.0 |
Leukemia, Lymphocytic, Acute/mortality/*therapy | 3 | 42.0 |
Life Tables | 3 | 1.0 |
Proportional Hazards Models | 2 | 0.0 |
Retrospective Studies | 28 | 0.0 |
Survival Analysis | 26 | 1.0 |
Tissue Donors | 3 | 1.0 |
Transplantation Conditioning | 3 | 5.0 |
Treatment Outcome | 44 | 1.0 |
Salvage Therapy | 3 | 4.0 |
Survival Rate | 24 | 1.0 |
*Chromosomes, Human, Pair 21 | 2 | 1.0 |
*Chromosomes, Human, Pair 8 | 2 | 0.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Prospective Studies | 7 | 0.0 |
*Translocation, Genetic | 2 | 0.0 |
B-Lymphocytes/cytology/*immunology | 4 | 5.0 |
Cell Line | 104 | 0.0 |
Cell Survival | 3 | 0.0 |
Complement 3/*metabolism | 19 | 11.0 |
Complement Pathway, Alternative | 4 | 3.0 |
Complement Pathway, Classical | 3 | 2.0 |
Erythrocytes/immunology | 8 | 3.0 |
In Vitro | 33 | 0.0 |
Kinetics | 16 | 0.0 |
Peptide Fragments/metabolism | 8 | 2.0 |
Receptors, Complement 3b/*metabolism | 2 | 10.0 |
Receptors, Complement 3d/*metabolism | 18 | 90.0 |
English Abstract | 14 | 0.0 |
Graft vs Host Disease/etiology | 7 | 12.0 |
Cells, Cultured | 33 | 0.0 |
Complement 3d/metabolism | 9 | 40.0 |
Complement Pathway, Alternative/*immunology | 5 | 31.0 |
Receptors, Complement 3b/immunology | 4 | 19.0 |
Receptors, Complement 3d/*immunology | 7 | 53.0 |
Antibodies, Anti-Idiotypic/pharmacology | 2 | 6.0 |
B-Lymphocytes/cytology/*immunology/*metabolism | 2 | 40.0 |
Heat | 2 | 0.0 |
Immunoglobulin M/immunology | 5 | 3.0 |
Intracellular Fluid/metabolism | 3 | 2.0 |
Lymphocyte Activation/immunology | 6 | 1.0 |
Phosphorylation | 19 | 0.0 |
Protein Binding/immunology | 7 | 3.0 |
Signal Transduction/*immunology | 7 | 1.0 |
Tyrosine/metabolism | 2 | 0.0 |
Animals | 145 | 0.0 |
Binding Sites | 39 | 0.0 |
CHO Cells | 2 | 0.0 |
COS Cells | 7 | 0.0 |
Cell Cycle | 4 | 0.0 |
Cell Division | 12 | 0.0 |
Exons | 6 | 0.0 |
Gene Expression Regulation | 8 | 0.0 |
Genes, Reporter | 5 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Hamsters | 4 | 0.0 |
Immunoblotting | 4 | 0.0 |
Immunohistochemistry | 13 | 0.0 |
Introns | 5 | 0.0 |
Models, Genetic | 2 | 0.0 |
Polymerase Chain Reaction | 15 | 0.0 |
Precipitin Tests | 14 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Recombinant Fusion Proteins/metabolism | 5 | 0.0 |
Recombinant Proteins/metabolism | 3 | 0.0 |
Retinoblastoma Protein/metabolism | 3 | 0.0 |
Trans-Activation (Genetics) | 8 | 0.0 |
Transfection | 22 | 0.0 |
Age Factors | 5 | 0.0 |
Antineoplastic Agents/administration & dosage | 2 | 6.0 |
Risk Factors | 8 | 0.0 |
Transplantation Conditioning/methods | 2 | 9.0 |
Whole-Body Irradiation | 10 | 12.0 |
Drug Resistance, Neoplasm | 2 | 0.0 |
*Hematopoietic Stem Cell Transplantation | 8 | 2.0 |
Time Factors | 15 | 0.0 |
Transplantation, Homologous/*immunology | 2 | 7.0 |
Graft vs Host Disease/prevention & control | 3 | 5.0 |
Histocompatibility Testing | 4 | 0.0 |
Leukemia, Myelocytic, Acute/mortality/*therapy | 4 | 36.0 |
Enzyme Inhibitors/pharmacology | 4 | 0.0 |
Mice | 103 | 0.0 |
Protein Structure, Tertiary | 9 | 0.0 |
Recombinant Fusion Proteins/physiology | 2 | 0.0 |
Binding, Competitive | 17 | 0.0 |
Jurkat Cells | 2 | 0.0 |
*Trans-Activation (Genetics) | 5 | 0.0 |
Transcription Factors/*metabolism | 2 | 0.0 |
Amino Acid Sequence | 65 | 0.0 |
Cercopithecus aethiops | 3 | 0.0 |
Chromosome Mapping | 5 | 0.0 |
Conserved Sequence | 9 | 0.0 |
Mutagenesis | 3 | 0.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Sequence Homology, Amino Acid | 8 | 0.0 |
Species Specificity | 13 | 0.0 |
DNA-Binding Proteins/metabolism | 3 | 0.0 |
*Gene Silencing | 2 | 1.0 |
K562 Cells | 2 | 0.0 |
Mutagenesis, Site-Directed | 8 | 0.0 |
Receptors, Complement 3d/biosynthesis/*genetics | 2 | 100.0 |
Regulatory Sequences, Nucleic Acid | 3 | 0.0 |
Alanine/genetics | 2 | 1.0 |
Amino Acid Substitution | 2 | 0.0 |
Cell Line, Transformed | 15 | 0.0 |
Gene Deletion | 2 | 0.0 |
*Genes, Viral | 2 | 1.0 |
Sequence Alignment | 7 | 0.0 |
Antibodies, Monoclonal/*immunology | 7 | 0.0 |
Antigen-Antibody Complex/immunology | 3 | 5.0 |
Complement 3b/metabolism | 17 | 16.0 |
Crystallography, X-Ray | 4 | 0.0 |
HIV-1/immunology | 2 | 2.0 |
Mice, Knockout | 2 | 0.0 |
Models, Molecular | 9 | 0.0 |
T-Lymphocytes/virology | 3 | 4.0 |
Viral Matrix Proteins/metabolism | 2 | 11.0 |
Apoptosis | 2 | 0.0 |
*Cell Cycle Proteins | 5 | 0.0 |
Tumor Stem Cell Assay | 2 | 1.0 |
B-Lymphocytes/immunology | 25 | 3.0 |
Biotin | 2 | 3.0 |
DNA, Complementary/genetics | 3 | 0.0 |
Ligands | 28 | 1.0 |
Protein Engineering | 2 | 2.0 |
Signal Transduction | 13 | 0.0 |
Gene Rearrangement | 2 | 0.0 |
Immunophenotyping | 5 | 0.0 |
Antibodies, Monoclonal/metabolism | 3 | 0.0 |
Blotting, Western | 10 | 0.0 |
Cell Adhesion | 4 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 15 | 0.0 |
Flow Cytometry | 32 | 0.0 |
Protein Binding | 21 | 0.0 |
Antigen Presentation | 3 | 0.0 |
Autoantigens/immunology/metabolism | 2 | 40.0 |
*Autoimmunity | 2 | 3.0 |
CD4-Positive T-Lymphocytes/*immunology | 3 | 0.0 |
Complement/*physiology | 7 | 7.0 |
Lymphocyte Activation | 26 | 0.0 |
Receptors, Complement/physiology | 5 | 26.0 |
*Bone Marrow Transplantation | 38 | 9.0 |
Tretinoin/therapeutic use | 2 | 7.0 |
Combined Modality Therapy | 28 | 2.0 |
*Hematopoietic Stem Cell Transplantation/adverse effects | 4 | 11.0 |
Complement/*immunology | 10 | 7.0 |
Complement Activation | 11 | 3.0 |
Receptors, Complement/immunology | 5 | 15.0 |
T-Lymphocytes/immunology | 10 | 0.0 |
Complement 3b/*metabolism | 16 | 17.0 |
Complement 3d/*metabolism | 8 | 72.0 |
Herpesvirus 4, Human/genetics/immunology/*metabolism | 2 | 100.0 |
Receptors, Complement 3d/genetics/*metabolism | 3 | 100.0 |
Surface Plasmon Resonance | 3 | 1.0 |
Cyclophosphamide/administration & dosage | 5 | 2.0 |
Neoplasm Metastasis | 2 | 0.0 |
Neoplasm Recurrence, Local | 4 | 0.0 |
Neoplasm Staging | 4 | 0.0 |
Escherichia coli | 2 | 0.0 |
Gene Expression Regulation, Viral | 5 | 1.0 |
Mutation | 13 | 0.0 |
Papillomavirus, Human/*physiology | 2 | 10.0 |
Virus Replication | 10 | 1.0 |
Biological Markers | 2 | 0.0 |
Spleen/cytology/immunology | 2 | 3.0 |
Antibodies, Monoclonal | 26 | 1.0 |
Consensus Sequence | 5 | 0.0 |
Protein Conformation | 9 | 0.0 |
Protein Structure, Secondary | 3 | 0.0 |
Receptors, Complement 3d/*chemistry/immunology/*metabolism | 2 | 100.0 |
Cell Count | 5 | 0.0 |
Transplantation, Homologous | 27 | 4.0 |
Dendritic Cells, Follicular/immunology | 2 | 50.0 |
Models, Biological | 9 | 0.0 |
Receptors, Complement 3d/*genetics | 4 | 100.0 |
Gene Expression | 10 | 0.0 |
Computer Simulation | 2 | 0.0 |
Repetitive Sequences, Amino Acid | 2 | 1.0 |
Structure-Activity Relationship | 12 | 0.0 |
Antibodies, Monoclonal/pharmacology | 6 | 0.0 |
Bucladesine/pharmacology | 2 | 1.0 |
Interleukin-4/pharmacology | 3 | 0.0 |
Nuclear Proteins/metabolism | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 7 | 0.0 |
3T3 Cells | 5 | 0.0 |
Cloning, Molecular | 21 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Nuclear Proteins/*metabolism | 5 | 0.0 |
Trans-Activators/*metabolism | 2 | 0.0 |
DNA/genetics/metabolism | 4 | 1.0 |
Herpesvirus 4, Human/*metabolism | 16 | 39.0 |
Membrane Glycoproteins/*metabolism | 3 | 0.0 |
NF-kappa B/*metabolism | 2 | 0.0 |
Promoter Regions (Genetics)/genetics | 4 | 0.0 |
RNA, Messenger/genetics/metabolism | 6 | 0.0 |
Receptors, Virus/metabolism | 2 | 3.0 |
Up-Regulation/drug effects | 3 | 0.0 |
Binding Sites/genetics | 5 | 0.0 |
Mice, Transgenic | 7 | 0.0 |
*Nuclear Proteins | 3 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 16 | 3.0 |
Recurrence/prevention & control | 2 | 5.0 |
Actuarial Analysis | 2 | 2.0 |
Bone Marrow Transplantation/*standards | 2 | 100.0 |
Graft vs Host Disease/mortality | 2 | 100.0 |
Cytarabine/administration & dosage | 11 | 12.0 |
Leukemia, Lymphocytic, Acute/*therapy | 3 | 18.0 |
Leukemia, Nonlymphocytic, Acute/*therapy | 2 | 33.0 |
Melphalan/administration & dosage | 4 | 8.0 |
Apoptosis/*immunology | 2 | 1.0 |
Hela Cells | 3 | 0.0 |
Microscopy, Confocal | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 3 | 1.0 |
Antigens, CD19/metabolism | 3 | 12.0 |
Herpesvirus 4, Human/immunology | 6 | 8.0 |
Immunoglobulins, Surface/metabolism | 2 | 10.0 |
Phosphoproteins/*metabolism | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Cell Nucleus/*metabolism | 3 | 0.0 |
Cell Transformation, Viral | 7 | 2.0 |
Fluorescent Antibody Technique | 11 | 0.0 |
*Antigen Presentation | 3 | 1.0 |
B-Lymphocytes/*immunology/*ultrastructure | 2 | 100.0 |
Microscopy, Immunoelectron | 4 | 0.0 |
Papillomavirus, Human/*genetics | 2 | 2.0 |
Graft vs Host Disease | 2 | 8.0 |
Lymphocyte Depletion | 2 | 1.0 |
Case-Control Studies | 4 | 0.0 |
DNA Primers/genetics | 5 | 0.0 |
T-Lymphocytes/*immunology | 7 | 0.0 |
Complement Activation/*genetics | 3 | 42.0 |
*Multigene Family | 4 | 0.0 |
Phylogeny | 3 | 0.0 |
Coculture Techniques | 2 | 0.0 |
Complement 3/*immunology | 9 | 13.0 |
HIV-1/*immunology | 5 | 1.0 |
T-Lymphocytes/immunology/*virology | 2 | 12.0 |
Tonsil/cytology | 6 | 7.0 |
Complement 3b Inactivators/metabolism | 3 | 12.0 |
Rosette Formation | 32 | 10.0 |
Solubility | 5 | 0.0 |
Antibodies, Monoclonal/immunology | 19 | 1.0 |
Down-Regulation | 2 | 0.0 |
Signal Transduction/drug effects | 2 | 0.0 |
Antigens, CD/genetics | 3 | 2.0 |
Receptors, Complement 3d/genetics | 2 | 66.0 |
Transcription, Genetic | 14 | 0.0 |
Culture Media | 3 | 0.0 |
Lymphokines/pharmacology | 2 | 1.0 |
B-Lymphocytes/immunology/metabolism | 4 | 7.0 |
Clone Cells | 3 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
Gene Expression Regulation/*immunology | 2 | 1.0 |
Immunization | 2 | 0.0 |
Sheep | 6 | 1.0 |
Receptors, Complement 3d/immunology/*metabolism | 3 | 75.0 |
Adenoviridae/*genetics | 2 | 0.0 |
Mice, Nude | 5 | 0.0 |
Antibody Formation/*immunology | 2 | 15.0 |
Antigen Presentation/immunology | 3 | 3.0 |
*Carrier Proteins | 3 | 0.0 |
*DNA-Binding Proteins | 6 | 0.0 |
Rats | 12 | 0.0 |
Retinoblastoma Protein/*metabolism | 4 | 2.0 |
U937 Cells | 2 | 0.0 |
*Leukapheresis | 2 | 5.0 |
Pilot Projects | 5 | 0.0 |
Bone Marrow Purging/*methods | 2 | 5.0 |
Cause of Death | 2 | 1.0 |
Disease Progression | 3 | 0.0 |
Feasibility Studies | 2 | 0.0 |
Antibody Formation | 8 | 1.0 |
B-Lymphocytes/metabolism | 5 | 2.0 |
Herpesvirus 4, Human/*immunology | 3 | 4.0 |
Receptors, Complement 3d/immunology | 12 | 66.0 |
Antibody Specificity | 8 | 0.0 |
Mice, Inbred BALB C | 10 | 0.0 |
Asparaginase/administration & dosage | 2 | 9.0 |
Bleomycin/administration & dosage | 2 | 2.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Lomustine/administration & dosage | 2 | 22.0 |
Prednisone/administration & dosage | 2 | 2.0 |
Vincristine/administration & dosage | 4 | 2.0 |
Hodgkin Disease/*therapy | 2 | 22.0 |
*Antibodies, Monoclonal | 2 | 0.0 |
Binding Sites, Antibody | 6 | 1.0 |
Epitopes/chemistry | 2 | 2.0 |
*Platelet Aggregation | 2 | 2.0 |
Complement 3b/*immunology | 4 | 16.0 |
Dimerization | 4 | 0.0 |
Receptors, Complement 3b/*immunology | 3 | 17.0 |
Granulocyte Colony-Stimulating Factor/administration & dosage | 2 | 7.0 |
*Hematopoietic Stem Cell Transplantation/mortality | 2 | 40.0 |
Antineoplastic Agents/*therapeutic use | 2 | 0.0 |
Receptors, Complement 3d/*immunology/metabolism | 2 | 100.0 |
Cell Culture Techniques | 4 | 0.0 |
Complement 3/metabolism | 20 | 7.0 |
Genes, Viral | 3 | 1.0 |
RNA, Messenger | 3 | 0.0 |
*Viral Proteins | 2 | 1.0 |
DNA/metabolism | 3 | 0.0 |
DNA-Binding Proteins/genetics/*metabolism | 3 | 0.0 |
Nuclear Proteins/genetics/*metabolism | 4 | 1.0 |
Repressor Proteins/genetics/*metabolism | 2 | 1.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Antigen-Antibody Complex/*metabolism | 2 | 2.0 |
B-Lymphocytes/immunology/*metabolism | 5 | 8.0 |
Complement/immunology | 4 | 4.0 |
Tonsil/immunology | 3 | 4.0 |
Methotrexate/therapeutic use | 2 | 3.0 |
Antibodies/immunology | 2 | 0.0 |
Antigen-Presenting Cells/immunology | 2 | 0.0 |
Dendritic Cells/immunology | 3 | 2.0 |
Immunoglobulin G/immunology | 3 | 0.0 |
Phenotype | 12 | 0.0 |
Receptors, Complement 3d/genetics/immunology | 2 | 100.0 |
Signal Transduction/immunology | 4 | 1.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Receptors, Complement 3d/*chemistry/metabolism | 2 | 100.0 |
Antibody Formation/*physiology | 2 | 18.0 |
Complement/*metabolism | 4 | 2.0 |
Immunity, Natural | 3 | 1.0 |
Microscopy, Electron | 7 | 0.0 |
Alternative Splicing | 2 | 0.0 |
DNA/genetics | 10 | 0.0 |
Herpesvirus 4, Human/*pathogenicity | 2 | 18.0 |
Repetitive Sequences, Nucleic Acid | 3 | 0.0 |
Molecular Weight | 26 | 0.0 |
Receptors, Complement 3d/metabolism | 3 | 42.0 |
Complement Activation/immunology | 3 | 9.0 |
src Homology Domains/immunology | 2 | 7.0 |
Antigen-Antibody Complex/*immunology | 3 | 3.0 |
*Lymphocyte Cooperation | 2 | 7.0 |
Neoplasm, Residual | 3 | 3.0 |
Predictive Value of Tests | 2 | 0.0 |
Antigens, CD/physiology | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/physiology | 6 | 30.0 |
Complement 3/physiology | 2 | 11.0 |
Receptors, Complement 3d/physiology | 2 | 40.0 |
Antigens, CD/*genetics | 2 | 0.0 |
Blotting, Northern | 7 | 0.0 |
Blotting, Southern | 3 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
DNA, Complementary | 2 | 0.0 |
*Linkage (Genetics) | 5 | 0.0 |
Membrane Glycoproteins/*genetics | 2 | 0.0 |
Antigen-Antibody Reactions | 5 | 1.0 |
Epitopes/immunology | 7 | 1.0 |
Herpesvirus 4, Human/metabolism | 9 | 47.0 |
Microspheres | 2 | 1.0 |
Models, Immunological | 2 | 0.0 |
Peptide Fragments/*metabolism | 4 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 9 | 1.0 |
Clinical Trials | 2 | 0.0 |
Cohort Studies | 2 | 0.0 |
Europe/epidemiology | 4 | 4.0 |
Philadelphia Chromosome | 2 | 4.0 |
Regression Analysis | 2 | 0.0 |
Leukemia, Myelocytic, Acute/*therapy | 2 | 8.0 |
Electric Stimulation | 2 | 0.0 |
Injections, Intramuscular | 2 | 1.0 |
Plasmids | 5 | 0.0 |
Antigens, CD/analysis | 5 | 0.0 |
Cell Separation | 12 | 1.0 |
Leukemia, Lymphocytic, Acute, L1/*therapy | 3 | 37.0 |
Cytotoxicity Tests, Immunologic | 3 | 0.0 |
Neutralization Tests | 2 | 0.0 |
Radioimmunoassay | 5 | 0.0 |
Leukemia/*therapy | 6 | 5.0 |
Etoposide/administration & dosage | 4 | 3.0 |
DNA, Viral/analysis | 4 | 1.0 |
Herpesvirus 4, Human/*genetics/immunology | 3 | 33.0 |
Complement 3d/*chemistry/metabolism | 2 | 100.0 |
Dose-Response Relationship, Immunologic | 2 | 0.0 |
Cell Differentiation/genetics/immunology | 2 | 2.0 |
Organ Specificity/genetics/immunology | 2 | 5.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Transcription, Genetic/immunology | 2 | 2.0 |
Immunity, Cellular | 3 | 0.0 |
B-Lymphocytes/*metabolism | 10 | 5.0 |
*Gene Expression Regulation | 3 | 0.0 |
Receptors, Complement/*genetics | 14 | 37.0 |
Cell Communication | 2 | 0.0 |
Drug Synergism | 3 | 0.0 |
Leukemia, Myelocytic, Acute/drug therapy/*therapy | 3 | 75.0 |
Antigens, CD/immunology | 2 | 0.0 |
Receptors, Antigen, B-Cell/*immunology | 2 | 5.0 |
Receptors, IgG/immunology | 3 | 8.0 |
Infusions, Intravenous | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 6 | 0.0 |
Oncogene Proteins, Viral/*physiology | 2 | 5.0 |
Leukemia, Lymphocytic, Acute, L1/mortality/*therapy | 2 | 100.0 |
Calcium/*physiology | 4 | 3.0 |
Receptors, Antigen, B-Cell/*physiology | 3 | 3.0 |
Spleen/cytology | 4 | 2.0 |
*Gene Expression Regulation, Viral | 5 | 1.0 |
HIV-1/*physiology | 2 | 0.0 |
Herpesvirus 4, Human/*physiology | 14 | 26.0 |
Transplantation, Autologous/adverse effects | 2 | 40.0 |
*Lymphocyte Activation | 11 | 0.0 |
Burkitt Lymphoma/*immunology | 2 | 10.0 |
Complement Activation/*immunology | 2 | 3.0 |
Herpesvirus 4, Human | 7 | 5.0 |
Bone Marrow Transplantation/*statistics & numerical data | 2 | 2.0 |
Cell Communication/immunology | 2 | 2.0 |
Leukocytes/*immunology | 5 | 3.0 |
*Cell Transformation, Neoplastic | 3 | 0.0 |
*Cell Transformation, Viral | 8 | 4.0 |
Receptors, Complement 3d | 117 | 90.0 |
Receptors, Complement/*metabolism | 22 | 20.0 |
Bone Marrow Cells | 2 | 0.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Receptors, Complement 3d/*biosynthesis | 2 | 66.0 |
*Oncogenes | 2 | 0.0 |
RNA, Messenger/analysis | 5 | 0.0 |
HIV Antibodies/*immunology | 4 | 4.0 |
HIV Envelope Protein gp41/*immunology | 2 | 9.0 |
Antigens, CD55/analysis | 2 | 10.0 |
B-Lymphocytes/*physiology | 12 | 8.0 |
Cell Differentiation | 10 | 0.0 |
B-Lymphocytes/drug effects/*metabolism | 2 | 9.0 |
Receptors, Complement/immunology/*physiology | 2 | 50.0 |
Mice, Inbred CBA | 2 | 0.0 |
Receptors, Complement 3d/analysis/immunology | 2 | 100.0 |
Sequence Deletion | 4 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Herpesvirus 4, Human/genetics/*physiology | 2 | 13.0 |
Cytotoxicity, Immunologic | 4 | 0.0 |
Killer Cells, Natural/*immunology | 5 | 1.0 |
Macrophages/*immunology | 4 | 1.0 |
Papillomavirus, Human/*metabolism | 2 | 18.0 |
Cell Division/immunology | 2 | 0.0 |
Cell Adhesion Molecules/analysis | 2 | 1.0 |
Lymphocytes/immunology | 2 | 0.0 |
Erythrocytes/*immunology | 3 | 1.0 |
Monocytes/immunology | 6 | 1.0 |
Neutrophils/immunology | 6 | 3.0 |
Phagocytosis/*immunology | 3 | 5.0 |
Antigen-Antibody Complex | 3 | 1.0 |
Immunity | 2 | 3.0 |
Antigens, CD/*immunology | 3 | 0.0 |
Antigens, CD19/immunology | 3 | 7.0 |
*Signal Transduction | 2 | 0.0 |
T-Lymphocytes/*metabolism | 4 | 1.0 |
Bone Marrow/*pathology | 2 | 1.0 |
Europe | 2 | 0.0 |
Receptors, Complement 3b/*physiology | 4 | 26.0 |
Immunosorbent Techniques | 3 | 1.0 |
Registries | 3 | 1.0 |
*Transplantation, Autologous | 2 | 33.0 |
Blood Cell Count | 2 | 0.0 |
Dexamethasone/administration & dosage | 2 | 6.0 |
Hematopoietic Stem Cell Transplantation/*methods/mortality | 2 | 25.0 |
Recombinant Proteins/pharmacology | 5 | 0.0 |
Epitopes/analysis | 3 | 1.0 |
Receptors, Virus/*metabolism | 10 | 10.0 |
Complement 3d/*immunology | 3 | 75.0 |
Hemocyanin/*immunology | 2 | 18.0 |
Leukocytes, Mononuclear/*immunology | 3 | 1.0 |
Lymphocyte Function-Associated Antigen-1/immunology | 2 | 7.0 |
*Bone Marrow Transplantation/adverse effects | 4 | 15.0 |
Promoter Regions (Genetics) | 5 | 0.0 |
Complement 3d | 17 | 22.0 |
Macromolecular Substances | 7 | 0.0 |
Receptors, Complement 3d/isolation & purification/*metabolism | 2 | 100.0 |
Dendritic Cells/*immunology | 2 | 0.0 |
Mice, Mutant Strains | 3 | 0.0 |
Receptors, Complement/genetics/*immunology | 2 | 28.0 |
Receptors, Complement/*chemistry | 3 | 75.0 |
Receptors, Complement 3d/analysis | 3 | 15.0 |
Transcription Factors/genetics/*metabolism | 2 | 0.0 |
Immunoenzyme Techniques | 5 | 0.0 |
Membrane Glycoproteins/analysis/*biosynthesis | 2 | 16.0 |
*Complement Activation | 6 | 1.0 |
Cell Division/drug effects | 5 | 0.0 |
Peptides/chemical synthesis/*pharmacology | 3 | 27.0 |
Proto-Oncogene Proteins c-raf | 3 | 2.0 |
*Proto-Oncogenes | 3 | 0.0 |
Tissue Distribution | 5 | 0.0 |
Receptors, Complement 3d/*analysis | 2 | 66.0 |
Cell Membrane/immunology | 11 | 4.0 |
Fluorescent Dyes | 5 | 1.0 |
Interleukin-1/biosynthesis | 2 | 1.0 |
N-Formylmethionine Leucyl-Phenylalanine/pharmacology | 3 | 1.0 |
RNA/biosynthesis | 3 | 3.0 |
Blood Platelets/*metabolism | 2 | 0.0 |
Chromatography, Affinity | 5 | 0.0 |
Neutrophils/*metabolism | 3 | 1.0 |
Lymphoma/*therapy | 2 | 14.0 |
Antigens, Viral/metabolism | 2 | 9.0 |
Receptors, Complement/*biosynthesis | 4 | 22.0 |
Antigens, CD/metabolism | 3 | 0.0 |
Enzyme Activation | 4 | 0.0 |
Proteins/*metabolism | 2 | 0.0 |
Receptors, Complement 3b/*analysis | 3 | 20.0 |
Infant, Newborn | 7 | 0.0 |
DNA, Complementary/analysis | 2 | 0.0 |
Phagocytosis/immunology | 2 | 3.0 |
Receptors, Complement 3b/metabolism | 3 | 14.0 |
Annexin A6 | 2 | 100.0 |
Ribonucleoproteins/*metabolism | 2 | 4.0 |
Antigens, CD19 | 7 | 4.0 |
Antigens, Differentiation, B-Lymphocyte/analysis | 5 | 2.0 |
Complement 4/analysis | 2 | 0.0 |
*Complement 4b | 2 | 6.0 |
Fluorescence | 2 | 0.0 |
Membrane Proteins/immunology | 5 | 9.0 |
Cyclophosphamide/*analogs & derivatives | 2 | 66.0 |
Antigens, CD18 | 2 | 2.0 |
*Cell Adhesion | 2 | 1.0 |
Phosphotyrosine | 3 | 1.0 |
Receptors, Complement/biosynthesis/*physiology | 2 | 100.0 |
Tumor Necrosis Factor-alpha/pharmacology | 2 | 0.0 |
KB Cells | 2 | 2.0 |
Kidney/metabolism | 2 | 0.0 |
Oligodeoxyribonucleotides | 2 | 0.0 |
Busulfan/administration & dosage | 2 | 11.0 |
*Chromosomes, Human, Pair 1 | 4 | 0.0 |
Evolution | 5 | 1.0 |
B-Lymphocytes/*microbiology | 2 | 20.0 |
Intercellular Adhesion Molecule-1 | 4 | 1.0 |
Receptors, Complement/metabolism | 8 | 13.0 |
Receptors, Virus/*physiology | 3 | 7.0 |
Antigens, CD55 | 11 | 5.0 |
*Complement Pathway, Alternative | 3 | 2.0 |
Membrane Glycoproteins/metabolism | 4 | 0.0 |
HIV Infections/*immunology | 3 | 0.0 |
Immunoglobulin G/analysis | 2 | 0.0 |
*Cell Cycle | 2 | 0.0 |
Complement 4b/*metabolism | 2 | 11.0 |
Antigen-Antibody Complex/metabolism | 2 | 3.0 |
Peptide Mapping | 3 | 0.0 |
Signal Transduction/physiology | 3 | 0.0 |
Bone Marrow Transplantation | 3 | 1.0 |
Immunoglobulin G/metabolism | 2 | 1.0 |
Opsonins/metabolism | 2 | 8.0 |
Temperature | 2 | 0.0 |
Adenovirus E1A Proteins/chemistry/genetics/*metabolism | 2 | 50.0 |
Cyclophosphamide/therapeutic use | 4 | 4.0 |
Receptors, Complement/genetics | 4 | 26.0 |
Receptors, Complement 3d/*genetics/metabolism | 2 | 100.0 |
Cell Membrane/*metabolism | 2 | 0.0 |
Lymphoma | 3 | 7.0 |
*Antigens, CD | 8 | 1.0 |
Immunologic Capping | 5 | 10.0 |
Antigens, T-Independent/immunology | 2 | 22.0 |
Cell Membrane/physiology | 2 | 1.0 |
HIV-1/immunology/*physiology | 4 | 7.0 |
Opsonins | 2 | 4.0 |
T-Lymphocytes/*microbiology | 3 | 9.0 |
Cholesterol Esters/pharmacology | 2 | 66.0 |
Complement 3b/immunology | 4 | 11.0 |
Virulence | 3 | 1.0 |
Up-Regulation | 2 | 0.0 |
Dogs | 2 | 0.0 |
Guinea Pigs | 3 | 0.0 |
Receptors, Complement/analysis | 3 | 5.0 |
Antigens, CD4/metabolism | 2 | 0.0 |
Glycoproteins/metabolism | 4 | 2.0 |
Lupus Erythematosus, Systemic/immunology | 4 | 3.0 |
Receptors, Virus/physiology | 4 | 16.0 |
Epitopes | 7 | 0.0 |
Sepharose | 2 | 3.0 |
*Complement Inactivators | 2 | 2.0 |
*Glycoproteins | 2 | 0.0 |
HIV Seropositivity/immunology | 2 | 2.0 |
Antigens, CD2 | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/*immunology | 4 | 5.0 |
Antigens, Differentiation, T-Lymphocyte/*immunology | 2 | 0.0 |
Antigens, Surface/immunology | 2 | 1.0 |
B-Lymphocytes/*immunology/metabolism | 2 | 4.0 |
Interleukin-2/pharmacology | 2 | 0.0 |
Burkitt Lymphoma | 7 | 8.0 |
Receptors, Immunologic/*metabolism | 2 | 1.0 |
Antigens, CD59 | 3 | 1.0 |
B-Lymphocytes | 3 | 1.0 |
RNA-Directed DNA Polymerase/biosynthesis | 2 | 20.0 |
Antigens, CD/*analysis | 5 | 0.0 |
Complement 3/analysis | 3 | 0.0 |
Membrane Glycoproteins/*analysis | 2 | 1.0 |
Antigens, CD/*physiology | 3 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/*physiology | 3 | 8.0 |
Complement 3d/chemical synthesis/*pharmacology | 2 | 100.0 |
Lymphocyte Activation/*drug effects | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/analysis/physiology | 2 | 50.0 |
Receptors, Complement/analysis/*physiology | 2 | 40.0 |
Antigens, Differentiation, B-Lymphocyte/metabolism | 10 | 17.0 |
Endocytosis | 8 | 2.0 |
Receptor Aggregation | 3 | 3.0 |
Receptors, Complement 3b | 44 | 13.0 |
Antigens, Differentiation, B-Lymphocyte/biosynthesis | 3 | 10.0 |
*Cytotoxicity, Immunologic | 2 | 0.0 |
Membrane Proteins/*analysis | 2 | 2.0 |
Receptors, Complement/*analysis | 13 | 16.0 |
Antigens, CD45 | 2 | 0.0 |
Histocompatibility Antigens/analysis | 2 | 3.0 |
Thymus Gland/*immunology | 2 | 3.0 |
DNA, Viral/*analysis | 2 | 2.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/genetics | 9 | 37.0 |
RNA Splicing | 2 | 0.0 |
RNA, Messenger/genetics | 5 | 0.0 |
DNA Probes | 3 | 0.0 |
Genetic Techniques | 2 | 2.0 |
Restriction Mapping | 8 | 0.0 |
Antibodies | 4 | 0.0 |
Receptors, Complement/genetics/isolation & purification/*physiology | 2 | 100.0 |
Complement Factor H | 6 | 7.0 |
Concanavalin A/metabolism | 2 | 7.0 |
Properdin/metabolism | 2 | 13.0 |
Rabbits | 7 | 0.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Immunoglobulins, Surface/physiology | 3 | 33.0 |
Phorbol Esters/pharmacology | 2 | 1.0 |
Receptors, Complement/*physiology | 9 | 16.0 |
Tyrosine/analogs & derivatives/metabolism | 2 | 1.0 |
Tumor Cells, Cultured/cytology | 2 | 10.0 |
Leukemia, Myelocytic, Acute/*surgery | 2 | 66.0 |
Antigens, Differentiation, B-Lymphocyte/immunology/metabolism | 2 | 22.0 |
Receptors, Complement/immunology/*metabolism | 3 | 37.0 |
Receptors, Complement/genetics/*metabolism | 2 | 28.0 |
Antibodies, Monoclonal/diagnostic use | 8 | 0.0 |
*Transfection | 3 | 1.0 |
*Viral Matrix Proteins | 3 | 37.0 |
Leukemia, Promyelocytic, Acute | 2 | 3.0 |
Herpesvirus 4, Human/*genetics | 3 | 4.0 |
Erythrocytes/metabolism | 4 | 2.0 |
X Chromosome | 2 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/genetics/metabolism | 2 | 40.0 |
Epstein-Barr Virus Nuclear Antigens | 4 | 9.0 |
Lymphocyte Activation/drug effects | 3 | 0.0 |
Oligonucleotides/chemistry | 2 | 1.0 |
Antigens, Differentiation, B-Lymphocyte/*analysis | 2 | 3.0 |
Herpesvirus 4, Human/physiology | 3 | 9.0 |
Linkage (Genetics) | 4 | 0.0 |
Antigens, Differentiation, B-Lymphocyte/immunology | 2 | 3.0 |
Leukocytes/immunology | 2 | 1.0 |
*Whole-Body Irradiation | 3 | 18.0 |
Antigens, Differentiation, B-Lymphocyte/analysis/immunology | 2 | 20.0 |
Receptors, Complement/*analysis/immunology | 8 | 44.0 |
Phagocytosis | 3 | 0.0 |
Immunoglobulin M/metabolism | 2 | 2.0 |
Membrane Proteins/metabolism | 2 | 0.0 |
Adenovirus Early Proteins | 2 | 2.0 |
Chromosome Deletion | 2 | 0.0 |
Oncogene Proteins, Viral/*genetics | 2 | 3.0 |
Complement Factor I | 3 | 14.0 |
Genes, Structural | 5 | 0.0 |
Antigens, Surface/*biosynthesis | 2 | 8.0 |
Genes, myc | 2 | 0.0 |
DNA/biosynthesis | 3 | 0.0 |
Antigens, Viral/*genetics | 2 | 11.0 |
Chemistry | 3 | 1.0 |
Multigene Family | 2 | 0.0 |
Receptors, Complement/*immunology | 21 | 31.0 |
*Receptors, Complement/genetics | 2 | 100.0 |
Antigens, Differentiation, B-Lymphocyte/*genetics | 3 | 14.0 |
Complement 3d/immunology | 3 | 60.0 |
Receptors, Virus/*analysis | 5 | 45.0 |
Methylamines/pharmacology | 2 | 9.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Cross Reactions | 3 | 0.0 |
Immunochemistry | 3 | 1.0 |
DNA/isolation & purification | 2 | 1.0 |
*Genes, Structural | 3 | 0.0 |
Receptors, Complement/*genetics/isolation & purification | 2 | 50.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Receptors, Complement/*immunology/metabolism | 2 | 18.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Monocytes/*immunology | 2 | 0.0 |
Complement 3/*physiology | 4 | 18.0 |
Antigens, Differentiation, B-Lymphocyte | 3 | 8.0 |
Interleukin-4 | 6 | 6.0 |
Interleukins/*physiology | 2 | 6.0 |
Mice/immunology | 2 | 8.0 |
Pedigree | 2 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Adsorption | 2 | 1.0 |
B-Lymphocytes/*cytology | 2 | 3.0 |
Antigen-Presenting Cells/*immunology | 2 | 1.0 |
Complement 4b | 4 | 4.0 |
B-Lymphocytes/*cytology/immunology | 2 | 6.0 |
Complement 3/immunology | 4 | 5.0 |
Cross-Linking Reagents | 2 | 0.0 |
Autoimmunity/*immunology | 2 | 4.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
*Complement | 2 | 3.0 |
T-Lymphocytes/analysis | 2 | 9.0 |
Antigens, Surface/analysis | 5 | 1.0 |
Immunoglobulins, Surface/analysis | 3 | 6.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Integrin alphaXbeta2 | 2 | 5.0 |
Burkitt Lymphoma/*pathology | 2 | 33.0 |
Complement 4/immunology | 3 | 7.0 |
B-Lymphocytes/*analysis | 5 | 35.0 |
Complement 4/metabolism | 4 | 4.0 |
Receptors, Virus/*genetics | 3 | 16.0 |
Leukemia, Myeloid, Chronic/*therapy | 2 | 14.0 |
Complement 3 | 4 | 10.0 |
Macrophage-1 Antigen | 6 | 12.0 |
*Receptors, Complement | 2 | 16.0 |
Histocytochemistry | 3 | 0.0 |
Trypsin | 2 | 1.0 |
Granulocytes/immunology | 3 | 5.0 |
Cell Membrane/analysis | 2 | 6.0 |
Evaluation Studies | 2 | 0.0 |
Preoperative Care | 2 | 1.0 |
Postoperative Complications | 2 | 1.0 |
Monocytes/metabolism | 2 | 0.0 |
Burkitt Lymphoma/immunology | 2 | 11.0 |
Peptide Fragments/immunology | 2 | 0.0 |
B-Lymphocytes/*analysis/immunology | 2 | 66.0 |
Neutrophils/*immunology | 2 | 1.0 |
Staining and Labeling | 2 | 0.0 |
Neutrophils/metabolism | 2 | 1.0 |
Antigens, Surface/*immunology | 2 | 1.0 |
B-Lymphocytes/analysis | 2 | 15.0 |
Alleles | 2 | 0.0 |
Complement 5/immunology | 2 | 11.0 |
Leukemia, Myeloid/*immunology | 2 | 5.0 |
Receptors, Fc/*analysis | 3 | 13.0 |
Leukemia, Lymphocytic/immunology | 2 | 7.0 |
